<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681044</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000595782</org_study_id>
    <secondary_id>BHO-H-25876</secondary_id>
    <secondary_id>BUMC-H-25876</secondary_id>
    <nct_id>NCT00681044</nct_id>
  </id_info>
  <brief_title>HD Melphalan and SCT in Patients With IGDD or LCDD</brief_title>
  <official_title>High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT) in Light-Chain Deposition Disease (LCDD) and Immunoglobulin Deposition Disease (IGDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a stem cell transplant stops the growth of cancer cells
      by stopping them from dividing or killing them. Giving colony-stimulating factors, such as
      G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the
      blood so they can be collected and stored. Chemotherapy is then given to prepare the bone
      marrow for the stem cell transplant. The stem cells are then returned to the patient to
      replace the blood-forming cells that were destroyed by the chemotherapy.

      PURPOSE: This phase II trial is studying the side effects of high-dose melphalan given
      together with stem cell transplant and to see how well it works in treating patients with
      immunoglobulin deposition disease or light-chain deposition disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To assess the tolerability of high-dose melphalan and autologous stem cell
           transplantation in patients with immunoglobulin deposition disease or light-chain
           deposition disease.

        -  To determine the hematologic response rate in patients treated with this regimen.

        -  To determine the predictability of early free light-chain response for heme response in
           patients treated with this regimen.

        -  To determine organ or clinical response in patients treated with this regimen.

        -  To determine overall survival of these patients.

      OUTLINE:

        -  Stem cell mobilization: Patients undergo blood stem cell mobilization comprising
           filgrastim (G-CSF) subcutaneously once daily for 3 days (i.e., through the day before
           the last stem cell collection).

        -  Stem cell collection: Patients undergo collection of G-CSF-mobilized blood stem cells
           until the target number of stem cells (at least 2 x 10^6 cluster of
           differentiation-34-positive cells) is reached.

        -  Conditioning regimen: Patients receive high-dose melphalan IV on days -3 to -2.

        -  Autologous stem cell transplantation: Patients undergo blood stem cell infusion on day
           0.

      After completion of study therapy, patients are followed at 3, 6, and 12 months and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematologic Response Rate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictability of Early Free Light-chain Response for Heme Response</measure>
    <time_frame>One month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ or Clinical Response</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>SCT with melphalan conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC</description>
    <arm_group_label>SCT with melphalan conditioning</arm_group_label>
    <other_name>G-CSF, neulasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>70-100 mg/m2/day will be administered intravenously on Days -3 and -2</description>
    <arm_group_label>SCT with melphalan conditioning</arm_group_label>
    <other_name>alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Infusion</intervention_name>
    <description>infusion of previously collected stem cells on Day 0</description>
    <arm_group_label>SCT with melphalan conditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed light-chain deposition disease based on the following
             criteria:

               -  Deposition of granular material containing free light-chain (FLC) immunoglobulins
                  that did not bind Congo red

               -  Evidence of a plasma cell dyscrasia, as defined by any of the following:

                    -  Monoclonal gammopathy in the serum or urine by immunofixation
                       electrophoresis

                    -  Clonal plasmacytosis on bone marrow biopsy by immuno-histochemical

                    -  Elevated serum levels of FLC

          -  Patients may enroll after stem cell collection (SCC) if all prestudy requirements are
             completed prior to starting SCC (i.e., ≥ 2.5 x 10^6 cells available for
             transplantation)

        PRIOR CONCURRENT THERAPY:

          -  Prior chemotherapy with alkylating agent allowed provided there is no evidence of
             myelodysplastic syndromes

          -  Prior total dose of melphalan &lt; 300 mg

          -  More than 4 weeks since prior cytotoxic therapy and recovered

        PATIENT CHARACTERISTICS:

          -  Performance status 0-2

          -  Left Ventricular Ejection Fraction (LVEF) ≥ 45% within the past 90 days

          -  diffusing capacity of lung for carbon monoxide (DLCO) ≥ 50%

        Exclusion Criteria:

          -  No overt multiple myeloma, as defined by any of the following:

               -  Greater than 30% bone marrow plasmacytosis

               -  Extensive (i.e., &gt; 2) lytic lesions

               -  Hypercalcemia

          -  No myocardial infarction, congestive heart failure, or arrhythmia refractory to
             therapy within the past 6 months

          -  No prior malignancy except adequately treated basal cell or squamous cell skin cancer,
             carcinoma in situ of the cervix, adequately treated stage I or II cancer from which
             the patient is currently in complete response, or any other cancer from which the
             patient has been disease-free for the past 5 years

          -  No HIV positivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaishali Sanchorawala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2008</study_first_submitted>
  <study_first_submitted_qc>May 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <results_first_submitted>January 26, 2017</results_first_submitted>
  <results_first_submitted_qc>January 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2017</results_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Vaishali Sanchorawala</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>monoclonal immunoglobulin deposition disease</keyword>
  <keyword>light chain deposition disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled from the Boston Medical Center Stem Cell Transplant Program between 2006 and 2009.</recruitment_details>
      <pre_assignment_details>A patient enrolled on this study but was withdrawn due to insufficient stem cell yield. His clinical situation changed 5 months later and the investigators believed he would have a better yield so he was enrolled for a second time. Therefore, there were 5 enrollments, but 4 patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SCT With Melphalan Conditioning</title>
          <description>Mobilization with Filgrastim Stem Cell collection (SCC) Melphalan Conditioning Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
melphalan: 70-100 mg/m2/day will be administered intravenously on Days –3 and –2
Stem Cell Infusion: infusion of previously collected stem cells on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SCT With Melphalan Conditioning</title>
          <description>Mobilization with Filgrastim Stem Cell collection Melphalan Conditioning Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
melphalan: 70-100 mg/m2/day will be administered intravenously on Days –3 and –2
Stem Cell Infusion: infusion of previously collected stem cells on Day 0</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hematologic Response Rate</title>
        <time_frame>one year</time_frame>
        <population>No data were collected or analyzed due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>SCT With Melphalan Conditioning</title>
            <description>Mobilization with Filgrastim Stem Cell collection Melphalan Conditioning Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
melphalan: 70-100 mg/m2/day will be administered intravenously on Days –3 and –2
Stem Cell Infusion: infusion of previously collected stem cells on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Hematologic Response Rate</title>
          <population>No data were collected or analyzed due to study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictability of Early Free Light-chain Response for Heme Response</title>
        <time_frame>One month</time_frame>
        <population>No data were collected or analyzed due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>SCT With Melphalan Conditioning</title>
            <description>Mobilization with Filgrastim Stem Cell collection Melphalan Conditioning Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
melphalan: 70-100 mg/m2/day will be administered intravenously on Days –3 and –2
Stem Cell Infusion: infusion of previously collected stem cells on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Predictability of Early Free Light-chain Response for Heme Response</title>
          <population>No data were collected or analyzed due to study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Organ or Clinical Response</title>
        <time_frame>One year</time_frame>
        <population>No data were collected or analyzed due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>SCT With Melphalan Conditioning</title>
            <description>Mobilization with Filgrastim Stem Cell collection Melphalan Conditioning Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
melphalan: 70-100 mg/m2/day will be administered intravenously on Days –3 and –2
Stem Cell Infusion: infusion of previously collected stem cells on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Organ or Clinical Response</title>
          <population>No data were collected or analyzed due to study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>life</time_frame>
        <population>No data were collected or analyzed due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>SCT With Melphalan Conditioning</title>
            <description>Mobilization with Filgrastim Stem Cell collection Melphalan Conditioning Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
melphalan: 70-100 mg/m2/day will be administered intravenously on Days –3 and –2
Stem Cell Infusion: infusion of previously collected stem cells on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>No data were collected or analyzed due to study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability</title>
        <time_frame>100 days</time_frame>
        <population>No data were collected or analyzed due to study termination</population>
        <group_list>
          <group group_id="O1">
            <title>SCT With Melphalan Conditioning</title>
            <description>Mobilization with Filgrastim Stem Cell collection Melphalan Conditioning Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
melphalan: 70-100 mg/m2/day will be administered intravenously on Days –3 and –2
Stem Cell Infusion: infusion of previously collected stem cells on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability</title>
          <population>No data were collected or analyzed due to study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>100 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SCT With Melphalan Conditioning</title>
          <description>Mobilization with Filgrastim Stem Cell collection Melphalan Conditioning Stem Cell infusion
filgrastim: 16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
melphalan: 70-100 mg/m2/day will be administered intravenously on Days –3 and –2
Stem Cell Infusion: infusion of previously collected stem cells on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>voice changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>joint pain</sub_title>
                <description>gout</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>increased creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <description>related to fluid overload</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>pulmonary edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic Epidermal Necrosis (TEN)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>line bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>sinus tacchycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>rigors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated ALT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>elevated alk phos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>joint pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <description>grand mal</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bilateral pleural effusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vaishali Sanchorawala, Director of Stem Cell Transplant Program</name_or_title>
      <organization>Boston Medical Center</organization>
      <phone>617-637-7017</phone>
      <email>vaishali.sanchorawala@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

